Please login to the form below

Not currently logged in
Email:
Password:

Alltracel to acquire German oral care company

UK-based Alltracel Pharmaceuticals is in an advanced stage of negotiations to acquire Synpart, a German-headquartered oral care and sports bandages company

Alltracel Pharmaceuticals, a UK-based healthcare group, has revealed it is in an advanced stage of negotiations to acquire Synpart, a German-headquartered oral care and sports bandages company

The negotiations so far reveal that Alltracel will acquire Synpart for EUR 6.3m. The initial consideration of EUR 5.3m will be met through a cash payment of EUR 3.3m and, following the acquisition, the issuance to the vendors of 10 per cent of ordinary shares in Westone, Alltracel's existing oral care subsidiary.

The cash consideration, together with additional working capital, will be met by a conditional cash placing to raise EUR 2.4m before expenses and by enlarging existing debt facilities from Bank of Scotland by EUR 3.1m.

On completion, Alltracel will issue 12,920,000 ordinary shares of EUR 0.0125 each in the share capital at a price of GBP 0.125 per ordinary share pursuant to the placing. A further cash payment of up to a maximum of EUR 1m will become payable to Synpart, subject to certain performance criteria, on the first anniversary of completion of the acquisition.

The acquisition should complete by 31 August 2007.

Synpart operates in Germany, Austria and Switzerland and has invested in technology and in particular in product design and has built a suite of patents and patent applications in the area of dental and oral care. Synpart also has a strong sourcing network in India.

FY06 turnover at Synpart was EUR 13.2m, with an EBITDA of EUR 1.2m and a pre-tax profit of EUR 468,000. Net assets were EUR 503,000.

Alltracel says that the acquisition of Synpart will secure leadership of the EU private label specialist Oral Care supply and wound management markets.

28th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics